Oncothyreon Inc. (ONTY) was a big mover last session, as the company saw its shares rise a little over 5% on the day. This rise can be attributable to solid volume too with far more shares changing hands than in a normal session. This continues the most recent uptrend of the company, as the stock is now up 14.04% in the past one-month time frame.

In the last 30 days, the company witnessed 2 upward and downward estimate revisions each while the Zacks Consensus Estimate has remained unchanged in the same period. However, the recent price action is encouraging, so make sure to keep a close watch on this firm in the near future.

Oncothyreon currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Some better-ranked biopharmaceutical stocks include Heska Corporation (HSKA), Actelion Ltd. (ALIOF) and AMAG Pharmaceuticals, Inc. (AMAG). All these stocks hold a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>




 
ACTELION LTD (ALIOF): Get Free Report
 
AMAG PHARMA INC (AMAG): Free Stock Analysis Report
 
HESKA CORP (HSKA): Free Stock Analysis Report
 
ONCOTHYREON INC (ONTY): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research
(USOTC:ALIOF)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024 Plus de graphiques de la Bourse
(USOTC:ALIOF)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024 Plus de graphiques de la Bourse